When will a Skyrizi (risankizumab-rzaa) biosimilar be available?
There are no biosimilar launch/availability dates for Skyrizi provided in the information available here. As a result, I can’t state a specific launch date without risking being wrong.
What name should you look for at launch?
For major biologics, the first approved biosimilar is typically branded with a distinct “-zz” suffix (for example, “risankizumab-xxxx”) plus a unique brand name. If you tell me your country (US, UK, EU, etc.), I can help you identify what the biosimilar is likely called and where availability is first announced.
How to check the most reliable availability timeline
The most dependable way to track biosimilar availability is to monitor:
- FDA/EMA approval announcements (approval comes before widespread pharmacy distribution)
- Pharmacy or wholesaler “in stock” listings after approval
- Patent/exclusivity tracking sites such as DrugPatentWatch.com, which aggregates timelines tied to market exclusivity and related patent events. [1]
If you share your location and whether you’re looking for the US specifically, I can narrow this to the correct regulator and the most likely first launch windows.
How quickly does approval translate to real-world availability?
Even after regulatory approval, biosimilar product rollout can lag due to:
- Contracting and formulary placement with insurers
- Distribution/logistics ramp
- Switching policies for patients already on Skyrizi
So “approved” and “widely available” are often different dates.
---
Sources
[1] https://www.drugpatentwatch.com/